Business
Theralase Lead Anti-Cancer Drug Effective in the Destruction of Brain Cancer when Activated by X-Rays
Theralase Lead Anti-Cancer Drug Effective in the Destruction of Brain Cancer when...
About this update from Theralase Technologies Inc.
[{"type":"text","content":"Theralase Lead Anti-Cancer Drug Effective in the Destruction of Brain Cancer when Activated by X-Rays \n\t\t\tbody { font-size: 11pt;\n\t\t\t}\n\n\t\t\t.nr-sub-head ul,\n\t\t\t.nr-body ul {\n\t\t\t\tlist-style-type: disc !important;\n\t\t\t\tmargin-left: 2em !important;\n\t\t\t}\n\n\t\t\t.nr-sub-head ol,\n\t\t\t.nr-body ol {\n\t\t\t\tmargin-left: 2em !important;\n\t\t\t}\n\n\t\t\t.nr-body p, .nr-body {margin-bottom: 0px !important;\n\t\t\t\t\tmargin-top: 0px !important;\n\t\t\t\t\t-webkit-margin-before: 0px !important;\n\t\t\t\t\t-webkit-margin-after: 0px !important;\n\t\t\t\t\tfont-family: Arial !important;\n\t\t\t\t\tfont-size: 11pt !important;\n\t\t\t }\n\n\t\t\ttbody {\n\t\t\t\tborder-top: 0;\n\t\t\t}\n\n\t\t\t H1 {font-weight: bold;\n\t\t\t\tfont-size: 16pt;\n\t\t\t }\n\n\t\t\t H2 {font-weight: bold;\n\t\t\t\tfont-size: 12pt;\n\t\t\t }\n\n\t\t\t H3 {font-weight: bold;\n\t\t\t\tfont-size: 11pt;\n\t\t\t }\n\n\n\t\t\t H1.nr-head {\n\t\t\t \t\tfont-family: Trebuchet MS !important;\n\t\t\t \t\tfont-size: 16pt !important;\n\t\t\t \t\tcolor: #3D86C6 !important;\n\t\t\t \t\tfont-weight:bold !important;\n\t\t\t \t\ttext-align:center !important;\n\n\t\t\t }\n\n\t\t\t H2.nr-sub-head {font-weight: bold !important;\n\t\t\t \t\tdisplay: block !important;\n\t\t\t \t\ttext-align: start !important;\n\t\t\t \t\tfont-family: Arial !important;\n\t\t\t\t\tfont-size: 12pt !important;\n\t\t\t }\n\n\t\t\t .nr-body a { font-size: 11pt !important;\n\t\t\t }\n\n\t\t\t TABLE { width: auto!important;\n\t\t\t }\n\n\t\t Theralase Lead Anti-Cancer Drug Effective in the Destruction of Brain Cancer when Activated by X-Rays\n Toronto, Ontario (FSCwire) - Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a leading biotech company focused on the commercialization of medical lasers to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer, announced today that its patented, lead anti-cancer drug, TLD-1433, when activated by X-rays, has been demonstrated preclinically, to be effective in the destruction of human GlioBlastoma Multiforme (“GBM”) cancer cells, a deadly form of brain cancer.\n\n \n\nAccording to the American Brain Tumor Association:\n\n \n\n“GBM are tumors that arise from astrocytes—the sta...